Show simple item record

dc.contributor.advisorCurrie, Margaret
dc.contributor.advisorHock, Barry
dc.contributor.advisorStrother, Matthew
dc.contributor.authorButt, Leah
dc.date.available2017-11-15T22:05:02Z
dc.date.copyright2017
dc.identifier.citationButt, L. (2017). Measuring Markers of Immune Response in Patients Treated with Nivolumab (Opdivo®) and Pembrolizumab (Keytruda®) (Thesis, Bachelor of Biomedical Sciences with Honours). University of Otago. Retrieved from http://hdl.handle.net/10523/7749en
dc.identifier.urihttp://hdl.handle.net/10523/7749
dc.description.abstractImmune checkpoint inhibitors (ICIs) have drastically improved the clinical outcome for many cancer patients. However, not all patients treated with ICIs show a clinical response and the development of a unique spectrum of adverse events, termed immune-related adverse events (irAEs), restricts their oncological applicability. Additionally, the production of anti-drug antibodies (ADAs) may negatively influence patient outcome, but their role during therapy is yet to be established due to limitations in standard detection techniques. The primary aim of this exploratory study was to identify biomarkers that predict patient outcome to prevent a proportion of individuals exposed to a potentially ineffective and/or harmful therapy. It was hypothesized that patients who develop anti-drug antibodies experience a decrease in treatment efficacy and/or an increase in toxicity. Furthermore, patients with differing outcomes in terms of response, survival and the development of toxicity may display distinct clinicopathological characteristics. A retrospective review was performed on 32 patients undergoing nivolumab or pembrolizumab monotherapy for metastatic melanoma. Blood serum trough samples from 8 pembrolizumab-treated patients were analysed using in-house developed ELISA’s to measure pembrolizumab and anti-pembrolizumab antibody levels. Of the patients reviewed, 23 (72%) were ineligible for inclusion in initial clinical trials of ICI drugs. 29 patients (91%) experienced irAEs and 13 (41%) progressed during treatment. No clinicopathological variables were found to significantly predict patient outcome. Anti-pembrolizumab antibodies were detected in one patient and correlated with decreased blood serum drug levels. In this patient case, the individual responded to treatment according to RECIST, but, developed irAEs (pneumonitis and infusion reactions). This study indicates that, patients who are ineligible for initial clinical trials may effectively be treated with immune checkpoint inhibitors. Further investigation in a larger cohort is required to determine the prevalence and role of anti-ICI antibodies during ICI-therapy.
dc.format.mimetypeapplication/pdf
dc.language.isoen
dc.publisherUniversity of Otago
dc.rightsAll items in OUR Archive are provided for private study and research purposes and are protected by copyright with all rights reserved unless otherwise indicated.
dc.titleMeasuring Markers of Immune Response in Patients Treated with Nivolumab (Opdivo®) and Pembrolizumab (Keytruda®)
dc.typeThesis
dc.date.updated2017-11-15T20:43:40Z
dc.language.rfc3066en
thesis.degree.disciplineDepartment of Pathology
thesis.degree.nameBachelor of Biomedical Sciences with Honours
thesis.degree.grantorUniversity of Otago
thesis.degree.levelHonours
otago.openaccessOpen
 Find in your library

Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record